Drugs / PBCLN-003
PBCLN-003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03793686 | Dec 2018 → Sep 2020 | Clostridium difficile colitis | Prolacta Bioscience | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05516225 | Sep 2016 → Feb 2017 | — | Prolacta Bioscience | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBCLN-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05516225 ↗ |
| Known as | HMO-Concentrate | “HMO-Concentrate derived from pooled donor breast milk was administered orally to 32 healthy adults for 7 days followed by 21 days of monitoring.” PMID 37652940 ↗ Aug 2023 |
| Known as | Human Milk Oligosaccharide Concentrate | “Phase 1 Safety Study of Human Milk Oligosaccharide Concentrate PBCLN-003 in Healthy Adult Volunteers” NCT05516225 ↗ |
| Modality | Other / unclassified | “complex mixture of human milk oligosaccharides (HMOs)” PMID 37652940 ↗ Aug 2023 |
| Route | Oral | “PBCLN-003, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts” NCT03793686 ↗ |